tirzepatide mastery course
Unit 8 of 12

Beyond Obesity

sleep apnea, liver disease, cardiovascular outcomes, and the expanding clinical portfolio

An Expanding Indication Map

Tirzepatide's clinical program extends well beyond diabetes and weight management. Eli Lilly is running or has completed trials in obstructive sleep apnea (SURMOUNT-OSA), metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), heart failure with preserved ejection fraction, and cardiovascular outcomes (SURPASS-CVOT). Some of these results have already led to new approvals. This unit covers the evidence for each indication, what's been approved, and what remains in the pipeline.

Indications Timeline

Track tirzepatide's expanding clinical portfolio from diabetes approval through emerging indications.

interactive indications timeline
25-29
ahi events/hour reduction in surmount-osa (first-ever fda-approved osa medication)
73.3%
mash resolution rate at 15 mg in synergy-nash phase 2 vs 13.2% with placebo
94%
diabetes risk reduction in prediabetic surmount-1 subgroup (not a dedicated prevention trial)
~13,300
patients enrolled in surpass-cvot, the cardiovascular outcomes trial vs dulaglutide
evidence strength varies across indications. Tirzepatide has FDA approvals for T2D, obesity, and OSA based on robust phase 3 data. The MASH data (SYNERGY-NASH) are phase 2 only, and the diabetes prevention signal comes from subgroup analyses, not a dedicated trial. Do not equate preliminary findings with confirmed clinical benefit.

key terms for this unit

A ahi clinical metric
Apnea-hypopnea index, the number of breathing interruptions per hour of sleep. Moderate-to-severe OSA is defined as AHI >=15 events/hour. SURMOUNT-OSA required this threshold for enrollment.
M mash liver disease
Metabolic dysfunction-associated steatohepatitis (formerly NASH). The inflammatory form of fatty liver disease that can progress to cirrhosis, liver failure, and liver cancer. Affects an estimated 5-6% of the global adult population.
M mace clinical endpoint
Major adverse cardiovascular events, typically defined as 3-point MACE (cardiovascular death, myocardial infarction, stroke). The primary endpoint in SURPASS-CVOT.
C cvot trial type
Cardiovascular outcomes trial. A large, long-duration trial required by regulators to assess whether a diabetes drug increases cardiovascular risk. SURPASS-CVOT compared tirzepatide to dulaglutide over approximately 4 years.
F fibrosis staging pathology
A grading system (F0-F4) for liver scarring severity. SYNERGY-NASH enrolled patients with F2 (moderate) or F3 (severe) fibrosis. Fibrosis improvement of >=1 stage was a key endpoint.